Vermillion Reports Fourth Quarter and Full Year 2011 Results

Vermillion, Inc. (NASDAQ: VRML ), a leading molecular diagnostics company, reported financial and operational results for the fourth quarter and full year ended December 31, 2011.

Q4 and Full Year 2011 Operational Highlights

• In 2011, the test volume of OVA1®, the company's flagship diagnostic designed to help differentiate benign from malignant ovarian masses, increased 147% to 15,225. In Q4, test volume increased 40% over the same year-ago quarter to 4,118.
• In 2011, expanded payer coverage for OVA1 with 10 additional independent Blue Cross Blue Shield plans, which brought the total to 22 by the end of the year. Collectively, OVA1 had coverage with approximately 82 million insured lives as of December 31, 2011.

  Published: 27 March 2012

  Written by Editor

  Nasdaq   Healthcare   Financial Results   Up on News   Interesting News  

  Read more: Vermillion Inc ( VRML )

Nordion to Launch Improved Physician Tools for TheraSphere® Liver Cancer Treatment at SIR Annual Scientific Meeting 2012

Company will also present expert speakers and introduce new iPad app

Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will be attending the Society for Interventional Radiologists (SIR) Annual Scientific Meeting 2012, taking place March 24-29 in San Francisco. The company will introduce several new or updated physician education tools and resources for TheraSphere®, Nordion's Y-90 microsphere treatment for liver cancer.

Skin Cancer Imaging with MoleMate™ Accelerates New Revenue Growth Strategy Via Entry Into Multiple Hundred Million Dollar Markets and On-Line Services

Expanded discussion at the Annual Shareholders' Meeting Scheduled for March 13, 2012 , 4 p.m. in Toronto at The National Club

MedX Health Corp., (TSXV: MDX.V - News) a global leader in drug free, non-invasive low level laser light therapy and light imaging systems, announced today that the Annual Shareholders' Meeting will be held on March 13, 2012 , at 4 p.m. at the National Club in Toronto , where the President and CEO, Steve Guillen will review how MoleMate has accelerated the transition into new markets, including on-line services.

Category I Code Approved for TranS1's AxiaLIF Pre-Sacral Interbody Fusion

TranS1 Inc. (Nasdaq:TSON - News), a medical device company focused on designing, developing and marketing minimally invasive spine products to treat degenerative conditions of the spine affecting the lower lumbar region, announced today that the American Medical Association ("AMA") Current Procedural Terminology ("CPT") Panel has voted to approve an application for a Category I CPT code for L5-S1 spinal fusion utilizing TranS1's pre-sacral interbody fusion approach with its AxiaLIF(R) implant. This coding change was recently disclosed on the AMA website and will become effective on January 1, 2013.